FOLR1 and ovarian cancer: In addition to its potential role as a clinical biomarker, there has been significant interest in using FRα as a therapeutic target in patients with ovarian cancer, with several FRα-targeted therapeutics, such as farletuzumab and mirvetuximab soravtansine, in late-phase trials [26–31].